Ignite Creation Date:
2024-05-06 @ 8:08 AM
Last Modification Date:
2024-10-26 @ 11:56 AM
Study NCT ID:
NCT02670252
Status:
COMPLETED
Last Update Posted:
2022-04-08
First Post:
2016-01-28
Brief Title:
BuCY vs TBICY Conditioning Regimen for Standard-risk ALL Undergoing Allo-HSCT
Sponsor:
Nanfang Hospital Southern Medical University
Organization:
Nanfang Hospital Southern Medical University
Study Overview
Official Title:
Busulfan Plus Cyclophosphamide vs Total Body Irradiation Plus Cyclophosphamide Conditioning Regimen for Standard-risk Acute Lymphocytic Leukemia Undergoing HLA-matched Allogeneic Hematopoietic Stem Cell Transplantation
Status:
COMPLETED
Status Verified Date:
2022-03
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Allogeneic hematopoietic stem cell transplantation allo-HSCT appears to be an efficient tool to cure standard-risk acute lymphocytic leukemia ALL in first CR CR1 but the choice between BU-based or TBI-based conditioning regimens still remains controversial In this study the safety and efficacy of BUCY and TBICY myeloablative conditioning regimens in patients undergoing allo-HSCT for ALL in CR1 are evaluated
Detailed Description:
Allo-HSCT appears to be an efficient tool to cure standard-risk ALL in CR1 The conditioning regimen with BUCY or TBICY is considered as the standard myeloablative regimen for ALL in CR1 but the choice between BU-based or TBI-based conditioning regimen still remains controversialIn order to analyze the impact of conditioning regimen on long-term survival and relapse in this study the safety and efficacy of BUCY and TBICY myeloablative conditioning regimens in patients undergoing allo-HSCT for ALL in CR1 are evaluated
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None